Cancer pathogenesis and therapy最新文献

{"title":"Current and future perspectives on the regulation and functions of miR-545 in cancer development","authors":"Jinze Shen,&nbsp;Xinming Su,&nbsp;Qurui Wang,&nbsp;Yufei Ke,&nbsp;Tianyu Zheng,&nbsp;Yunan Mao,&nbsp;Zehua Wang,&nbsp;Jingyin Dong,&nbsp;Shiwei Duan","doi":"10.1016/j.cpt.2023.09.001","DOIUrl":"10.1016/j.cpt.2023.09.001","url":null,"abstract":"<div><p>Micro ribonucleic acids (miRNAs) are a highly conserved class of single-stranded non-coding RNAs. Within the miR-545/374a cluster, miR-545 resides in the intron of the long non-coding RNA (lncRNA) <em>FTX</em> on Xq13.2. The precursor form, pre-miR-545, is cleaved to generate two mature miRNAs, miR-545-3p and miR-545-5p. Remarkably, these two miRNAs exhibit distinct aberrant expression patterns in different cancers; however, their expression in colorectal cancer remains controversial. Notably, miR-545-3p is affected by 15 circular RNAs (circRNAs) and 10 long non-coding RNAs (lncRNAs), and it targets 27 protein-coding genes (PCGs) that participate in the regulation of four signaling pathways. In contrast, miR-545-5p is regulated by one circRNA and five lncRNAs, it targets six PCGs and contributes to the regulation of one signaling pathway. Both miR-545-3p and miR-545-5p affect crucial cellular behaviors, including cell cycle, proliferation, apoptosis, epithelial-mesenchymal transition, invasion, and migration. Although low miR-545-3p expression is associated with poor prognosis in three cancer types, studies on miR-545-5p are yet to be reported. miR-545-3p operates within a diverse range of regulatory networks, thereby augmenting the efficacy of cancer chemotherapy, radiotherapy, and immunotherapy. Conversely, miR-545-5p enhances immunotherapy efficacy by inhibiting T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) expression. In summary, miR-545 holds immense potential as a cancer biomarker and therapeutic target. The aberrant expression and regulatory mechanisms of miR-545 in cancer warrant further investigation.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 142-154"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000514/pdfft?md5=9e5c92ec4875e6931dceda6cb3c4ade8&pid=1-s2.0-S2949713223000514-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74087025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Common endocrine system adverse events associated with immune checkpoint inhibitors","authors":"Ying Li ,&nbsp;Junfeng Zhao ,&nbsp;Yue Wang ,&nbsp;Yali Xu ,&nbsp;Ruyue Li ,&nbsp;Ying Zhao ,&nbsp;Xue Dong ,&nbsp;Xiujing Yao ,&nbsp;Yintao Li","doi":"10.1016/j.cpt.2023.11.005","DOIUrl":"10.1016/j.cpt.2023.11.005","url":null,"abstract":"<div><p>Immune checkpoint inhibitors (ICIs), a novel anti-tumor therapeutic modality, are monoclonal antibodies targeting certain immune checkpoints (ICs) that reactivate T cells to achieve anti-tumor immunity by targeting, binding, and blocking ICs. Targeted inhibitory antibodies against the ICs cytotoxic T-lymphocyte antigen and programmed death receptor-1 have demonstrated efficacy and durable anti-tumor activity in patients with cancer. ICs may prevent autoimmune reactions. However, ICIs may disrupt ICs properties and trigger autoimmune-related adverse reactions involving various organ systems including the cardiovascular, pulmonary, gastrointestinal, renal, musculoskeletal, dermal, and endocrine systems. Approximately 10% of patients with damage to target organs such as the thyroid, pituitary, pancreas, and adrenal glands develop endocrine system immune-related adverse events (irAEs) such as thyroid dysfunction, pituitary gland inflammation, diabetes mellitus, and primary adrenal insufficiency. However, the symptoms of immunotherapy-associated endocrine system irAEs may be nonspecific and similar to those of other treatment-related adverse reactions, and failure to recognize them early may lead to death. Timely detection and treatment of immunotherapy-associated endocrine irAEs is essential to improve the efficacy of immunotherapy, prognosis, and the quality of life of patients. This study aimed to review the mechanisms by which ICIs cause endocrine irAEs providing guidance for the development of appropriate management protocols. Here, we discuss (1) the biological mechanisms of ICs in tumorigenesis and progression, focusing on cytotoxic T-lymphocyte antigen and programmed cell death-1/programmed cell death-ligand 1; and (2) the epidemiology, clinical symptoms, diagnosis, and treatment of four immunotherapy-related endocrine complications.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 164-172"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000940/pdfft?md5=9b567190c1c0ea502bbe5918ef7f6a38&pid=1-s2.0-S2949713223000940-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138622530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heavy metal exposure as a risk factor in oral cancer","authors":"Raja Kamalesh,&nbsp;Anbalagan Saravanan","doi":"10.1016/j.cpt.2024.05.002","DOIUrl":"https://doi.org/10.1016/j.cpt.2024.05.002","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 215-216"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713224000314/pdfft?md5=eafb78ce4d3f9b6d4aefd59f01854aeb&pid=1-s2.0-S2949713224000314-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141540839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover","authors":"","doi":"10.1016/S2949-7132(24)00033-8","DOIUrl":"https://doi.org/10.1016/S2949-7132(24)00033-8","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Page OFC"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713224000338/pdfft?md5=719ec03b8c57dcd2c08a08e1b1f320f1&pid=1-s2.0-S2949713224000338-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141542534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer","authors":"Siddhant Shukla ,&nbsp;Harsh Patel ,&nbsp;Shuzhen Chen ,&nbsp;Rainie Sun ,&nbsp;Liuya Wei ,&nbsp;Zhe-Sheng Chen","doi":"10.1016/j.cpt.2023.10.003","DOIUrl":"10.1016/j.cpt.2023.10.003","url":null,"abstract":"<div><p>Dostarlimab, a programmed death receptor-1 (PD-1)-blocking IgG4 humanized monoclonal antibody, gained accelerated approval from the US Food and Drug Administration (FDA) in April 2021, and received a full approval in February 2023. Dostarlimab was approved for treating adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC) that progressed during or after prior treatment who have no other suitable treatment options. Herein, we review the structure-based mechanism of action of dostarlimab and the results of a clinical study (GARNET; NCT02715284) to comprehensively clarify the efficacy and toxicity of the drug. The efficacy and safety of dostarlimab as monotherapy was assessed in a non-randomized, multicenter, open-label, multi-cohort trial that included 209 patients with dMMR recurrent or advanced solid tumors after receiving systemic therapy. Patients received 500 mg of dostarlimab intravenously every three weeks until they were given four doses. Then, patients received 1000 mg dostarlimab intravenously every six weeks until disease progression or unacceptable toxicity. The overall response rate, as determined by shrinkage in tumor size, was 41.6% (95% confidence interval [CI]; 34.9, 48.6), with 34.7 months as the median response duration. In conclusion, dostarlimab is an immunotherapy-based drug that has shown promising results in adult patients with recurrent or advanced dMMR EC. However, its efficacy in other cancer subtypes, the development of resistance to monotherapy, and efficacy and safety in combination with other immunotherapeutic drugs have not yet been studied.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 135-141"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S294971322300085X/pdfft?md5=da6c271bd6c1eecc55a01fce646df3ba&pid=1-s2.0-S294971322300085X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135852344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology","authors":"Yutong Wang,&nbsp;Mengzhen Wang,&nbsp;Bin Chu,&nbsp;Minqiu Lu,&nbsp;Lei Shi,&nbsp;Shan Gao,&nbsp;Yuan Chen,&nbsp;Qin Yan,&nbsp;Na Ji,&nbsp;Li Bao","doi":"10.1016/j.cpt.2023.12.004","DOIUrl":"10.1016/j.cpt.2023.12.004","url":null,"abstract":"<div><h3>Background</h3><p>Multiple myeloma (MM) is a heterogeneous plasma-derived hematopoietic malignancy with complex genetic mutation contributing to the pathogenesis. Though gene sequencing has been applied in MM, genetic features from Chinese MM patients are reported less. We investigated the genetic mutation of newly diagnosed multiple myeloma (NDMM) patients and explore its correlation with cytogenetic abnormalities detected by fluorescence <em>in situ</em> hybridization (FISH).</p></div><div><h3>Methods</h3><p>A total of 206 patients with NDMM were enrolled. After enriching plasma cells with CD138 magnetic beads, 92 MM-related target gene mutations were detected by the Illumina sequencing platform, and six common genetic abnormalities were detected by FISH.</p></div><div><h3>Results</h3><p>162 cases (78.6%) had at least one gene mutation detected by NDMM. The top 5 mutated genes were <em>KRAS, NRAS, TRAF3, BRAF,</em> and <em>TP53</em>. Cytogenetic abnormalities detected by FISH have a certain correlation with gene mutations, t(11;14) translocations are often accompanied by <em>CCND1</em> and <em>TP53</em> mutations, <em>KLHL6</em> in t(4;14), <em>SP140, CDKN1B</em> and <em>PRKD2</em> in t(14;16) and t(14;20) translocations. The mutation ratio was higher for <em>EGR1</em>, while lower of <em>CCND1</em> in patients with gain 1q21. The <em>TP53</em> mutation was more likely in patients with 17p deletion. The gene mutation affects the pathway of the RNA process is more frequently occurring in males and age less than 70 years patients. The International Staging System (ISS) Stage III correlated with gene mutations in the NK-κB pathway while Revised ISS (R-ISS) Stage III correlated with the DNA damage repair pathway.</p></div><div><h3>Conclusions</h3><p>There are various gene mutations in NDMM patients, mainly <em>RAS/MAPK</em> and <em>NF-κB</em> pathway gene pathways.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 205-211"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223001076/pdfft?md5=9285f36ca2dc2be16e66fba9ec679478&pid=1-s2.0-S2949713223001076-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139395948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overlap in oncogenic and pro-inflammatory pathways associated with areca nut and nicotine exposure","authors":"Krati Garg ,&nbsp;Anuj Kumar ,&nbsp;Vidisha Kizhakkethil ,&nbsp;Pramod Kumar ,&nbsp;Shalini Singh","doi":"10.1016/j.cpt.2023.09.003","DOIUrl":"10.1016/j.cpt.2023.09.003","url":null,"abstract":"<div><h3>Background</h3><p>Betel nut/areca nut/<em>Areca catechu</em> is one of the most commonly used psychoactive substance, and is also a major preventable cause of cancer. Unlike other psychoactive substances, such as nicotine, the mechanisms underlying addiction to areca nuts and related oncogenesis remain elusive. Recent reports suggest a possible overlap in the mechanisms of action of nicotine and areca nuts in the human body. Thus, this study aimed to investigate the interactome of human proteins associated with areca nut exposure and the intricate similarities and differences in the effects of the two psychoactive substances on humans.</p></div><div><h3>Methods</h3><p>A list of proteins associated with areca nut use was obtained from the available literature using terms from Medical Subject Headings (MeSH). Protein-protein interaction (PPI) networks and functional enrichment were analyzed. The results obtained for both psychoactive substances were compared.</p></div><div><h3>Results</h3><p>Given the limited number of common proteins (36/226, 16%) in the two sets, a substantial overlap (612/1176 nodes, 52%) was observed in the PPI networks, as well as in Gene Ontology. Areca nuts mainly affect signaling pathways through three hub proteins (alpha serine/threonine-protein kinase, tumor protein 53, and interleukin-6), which are common to both psychoactive substances, as well as two unique hub proteins (epidermal growth factor receptor and master regulator of cell cycle entry and proliferative metabolism). Areca nut-related proteins are associated with unique pathways, such as extracellular matrix organization, lipid storage, and metabolism, which are not found in nicotine-associated proteins.</p></div><div><h3>Conclusions</h3><p>Areca nuts affect regulatory mechanisms, leading to systemic toxicity and oncogenesis. Areca nuts also affect unique pathways that can be studied as potential markers of exposure, as well as targets for anticancer therapeutic agents.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 187-194"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000538/pdfft?md5=b53504edae65d6c0b6c5194a5a7c7804&pid=1-s2.0-S2949713223000538-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135348578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between visceral obesity and prognosis in patients with stage IVB cervical cancer receiving radiotherapy and chemotherapy","authors":"Chao Ji,&nbsp;Silin Liu,&nbsp;Che Wang,&nbsp;Jie Chen,&nbsp;Jin Wang,&nbsp;Xinyue Zhang,&nbsp;Jinlu Ma,&nbsp;Mengjiao Cai","doi":"10.1016/j.cpt.2023.09.002","DOIUrl":"10.1016/j.cpt.2023.09.002","url":null,"abstract":"<div><h3>Background</h3><p>Concurrent chemoradiotherapy is the preferred treatment for stage IVB cervical cancer; however, some patients experience a poor prognosis. The prognostic significance of body composition indicators, including visceral obesity, has been extensively investigated in patients with cancer. This study aimed to assess the impact of body composition indicators, specifically pretreatment fat content, on the survival outcomes of patients with stage IVB cervical cancer.</p></div><div><h3>Methods</h3><p>We retrospectively analyzed clinical information from patients diagnosed with stage IVB cervical cancer between 2010 and 2018. We measured visceral obesity (visceral-to-subcutaneous adipose tissue area ratio [VSR]) and skeletal muscle index (SMI) on pretreatment computed tomography (CT) images. We evaluated the impact of these body composition parameters on the prognosis of patients with cervical cancer.</p></div><div><h3>Results</h3><p>Overall, 116 patients were included, 81 of whom had complete clinical and imaging information. Based on the cut-off values from X-tile analysis, we categorized patients into high and low VSR and SMI groups. The overall survival (OS) rate of patients with a high VSR was significantly higher than that of patients with a low VSR (<em>P</em> = 0.022). Multivariate Cox regression analysis showed that a low VSR was an independent risk factor for the prognosis of patients with stage IVB cervical cancer.</p></div><div><h3>Conclusion</h3><p>Visceral obesity before radiotherapy and chemotherapy has a protective effect on the prognosis of patients with stage IVB cervical cancer, while low muscle index and VSR are associated with poor prognosis.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 180-186"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000526/pdfft?md5=06cf2a97d07151a9047f6bd66510398a&pid=1-s2.0-S2949713223000526-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135387622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing post-treatment outcomes in patients with oral cancer: Integrating interventions and psychosocial support","authors":"Ponnambalam Ragini Yaashikaa","doi":"10.1016/j.cpt.2024.06.005","DOIUrl":"10.1016/j.cpt.2024.06.005","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 4","pages":"Pages 318-320"},"PeriodicalIF":0.0,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713224000466/pdfft?md5=7427177f4f8429c29640eb8efb78b26e&pid=1-s2.0-S2949713224000466-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New insights into digestive tract tumors","authors":"Zhidong Gao,&nbsp;Zhanlong Shen,&nbsp;Shuo Wang,&nbsp;Yingjiang Ye","doi":"10.1016/j.cpt.2024.06.002","DOIUrl":"10.1016/j.cpt.2024.06.002","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 4","pages":"Pages 217-218"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713224000430/pdfft?md5=644cd2522c4a9c8bfad1b2b01e167769&pid=1-s2.0-S2949713224000430-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}